UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

An efficient algorithm for multiple polony detection

2008 5th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, 2008, p.716-719

2008

Volltextzugriff (PDF)

The Wistar Audiogenic Rat (WAR) strain and its contributions to epileptology and related comorbidities: History and perspectives

Epilepsy & behavior, 2017-06, Vol.71 (Pt B), p.250-273

2017

Volltextzugriff (PDF)

ATP13A3 is a major component of the enigmatic mammalian polyamine transport system

The Journal of biological chemistry, 2021-01, Vol.296, p.100182, Article 100182

2021

Volltextzugriff (PDF)

Marginal bone loss around implants placed in maxillary native bone or grafted sinuses: a retrospective cohort study

Clinical oral implants research, 2014-03, Vol.25 (3), p.378-384

2014

Volltextzugriff (PDF)

LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis

Annals of oncology, 2023-11, Vol.34, p.S1467-S1468

2023

Volltextzugriff (PDF)

1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)

Annals of oncology, 2020-11, Vol.31, p.S1241-S1242

2020

Volltextzugriff (PDF)

RNAseq profiling of primary microglia and astrocyte cultures in near-term ovine fetus: A glial in vivo-in vitro multi-hit paradigm in large mammalian brain

Journal of neuroscience methods, 2017-01, Vol.276, p.23-32

2017

Volltextzugriff (PDF)

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)

Annals of oncology, 2017-09, Vol.28, p.v72-v72

2017

Volltextzugriff (PDF)

LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

Annals of oncology, 2023-10, Vol.34, p.S1260-S1261

2023

Volltextzugriff (PDF)

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Annals of oncology, 2019-10, Vol.30, p.v853-v854

2019

Volltextzugriff (PDF)

135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

Annals of oncology, 2022-09, Vol.33, p.S600-S601

2022

Volltextzugriff (PDF)

LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study

Annals of oncology, 2023-10, Vol.34, p.S1257-S1257

2023

Volltextzugriff (PDF)

359TiP International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)

Annals of oncology, 2020-09, Vol.31, p.S394-S395

2020

Volltextzugriff (PDF)

5116 POSTER Evidence of No Benefit for Extensive Axillary Dissection in Lymph Node-positive Early Breast Cancer Treated With Adjuvant Radiation

European journal of cancer (1990), 2011, Vol.47, p.S364-S365

2011

Volltextzugriff (PDF)

5113 POSTER Getting Deep in the Luminal B Breast Cancer Subtype and Its Ki67 Cutoff Value

European journal of cancer (1990), 2011, Vol.47, p.S363-S364

2011

Volltextzugriff (PDF)

LBA8_PR - KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Annals of oncology, 2019-10, Vol.30, p.v853-v854

2019

Volltextzugriff (PDF)

183MO Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): Second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial

ESMO open, 2024-05, Vol.9, p.103205, Article 103205

2024

Volltextzugriff (PDF)

187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial

ESMO open, 2023-05, Vol.8 (1), p.101376, Article 101376

2023

Volltextzugriff (PDF)

Histomoniasis in the Bursa of Fabricius of Chickens

Avian diseases, 2004-09, Vol.48 (3), p.711-715

2004

Volltextzugriff (PDF)

Progress in the integration of Test Blanket Systems in ITER equatorial port cells and in the interfaces definition

Fusion engineering and design, 2012-08, Vol.87 (7-8), p.1347-1351

2012

Volltextzugriff (PDF)

Vitamin A deficiency in turkey poults

Journal of veterinary diagnostic investigation, 2006-09, Vol.18 (5), p.489-494

2006

Volltextzugriff (PDF)

Omphalitis Associated with Aspergillus fumigatus in Poults

Avian diseases, 2005-06, Vol.49 (2), p.304-308

2005

Volltextzugriff (PDF)

Otitis Interna (Labyrinthitis) Associated with Salmonella enterica arizonae in Turkey Poults

Avian diseases, 2006-03, Vol.50 (1), p.135-138

2006

Volltextzugriff (PDF)

Polymer: Bioceramic composites optimization by tetracycline addition

International journal of pharmaceutics, 2007-05, Vol.336 (1), p.75-81

2007

Volltextzugriff (PDF)

Improvement of irrigation management towards the sustainable use of groundwater in Castilla-La Mancha, Spain

Agricultural water management, 1999-05, Vol.40 (2), p.195-205

1999

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(27)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An efficient algorithm for multiple polony detection

The Wistar Audiogenic Rat (WAR) strain and its contributions to epileptology and related comorbidities: History and perspectives

ATP13A3 is a major component of the enigmatic mammalian polyamine transport system

Marginal bone loss around implants placed in maxillary native bone or grafted sinuses: a retrospective cohort study

LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis

1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)

RNAseq profiling of primary microglia and astrocyte cultures in near-term ovine fetus: A glial in vivo-in vitro multi-hit paradigm in large mammalian brain

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)

LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study

359TiP International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)

5116 POSTER Evidence of No Benefit for Extensive Axillary Dissection in Lymph Node-positive Early Breast Cancer Treated With Adjuvant Radiation

5113 POSTER Getting Deep in the Luminal B Breast Cancer Subtype and Its Ki67 Cutoff Value

LBA8_PR - KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

183MO Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): Second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial

187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial

Histomoniasis in the Bursa of Fabricius of Chickens

Progress in the integration of Test Blanket Systems in ITER equatorial port cells and in the interfaces definition

Vitamin A deficiency in turkey poults

Omphalitis Associated with Aspergillus fumigatus in Poults

Otitis Interna (Labyrinthitis) Associated with Salmonella enterica arizonae in Turkey Poults

Polymer: Bioceramic composites optimization by tetracycline addition

Improvement of irrigation management towards the sustainable use of groundwater in Castilla-La Mancha, Spain

Suchergebnisse filtern